



Extracellular Vesicles and Lipid Nanoparticles in Cardiovascular Diseases

Guest Editor:

Dr. Junlang Li

1. Department of Molecular Biomedical Sciences and Comparative Medicine Institute, North Carolina State University, Raleigh, NC, USA

2. Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill & Raleigh, NC, USA

Deadline for manuscript submissions:

31 December 2024

Message from the Guest Editor

This Special Issue encourages authors to develop innovative solutions by concurrently exploring extracellular vesicles and lipid nanoparticles. Extracellular vesicles (EVs) have recently emerged as pivotal mediators in intercellular communication during cardiovascular development and pathophysiology, with exosomal non-coding RNAs offering promise as diagnostic and prognostic biomarkers for CVDs. Simultaneously, lipid nanoparticles (LNPs) present themselves as versatile carriers, offering potential solutions for targeted drug delivery in cardiovascular therapies. This Research Topic seeks original research and review articles, offering to provide a platform to research navigating challenges such as EV/LNP manufacturing, RNA-loaded EVs/LNPs, and targeted delivery. Authors are encouraged to delve into diverse themes, from the differentiation of cardiovascular cells to diagnostic innovations and cardiovascular homeostasis, fostering a comprehensive understanding of both extracellular vesicles and lipid nanoparticles in the context of cardiovascular translational medicine.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI